Perez-Ruixo, Carlos
Rossenu, Stefaan
Zannikos, Peter
Nandy, Partha
Singh, Jaskaran
Drevets, Wayne C.
Perez-Ruixo, Juan Jose
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Documents that mention this clinical trial
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Documents that mention this clinical trial
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Documents that mention this clinical trial
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Documents that mention this clinical trial
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Documents that mention this clinical trial
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Documents that mention this clinical trial
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Documents that mention this clinical trial
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Documents that mention this clinical trial
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Documents that mention this clinical trial
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Documents that mention this clinical trial
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Documents that mention this clinical trial
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
https://doi.org/10.1007/s40263-022-00916-2
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Documents that mention this clinical trial
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40262-020-00953-4
Article History
Accepted: 6 October 2020
First Online: 31 October 2020
Declarations
:
: The clinical studies were supported by research funding from Janssen Research and Development, and the analyses presented here were supported by Janssen Research and Development.
: Stefaan Rossenu, Peter Zannikos, Partha Nandy, Jaskaran Singh, Wayne Drevets, and Juan Jose Perez Ruixo were employees and shareholders of Janssen Pharmaceutical Companies at the time this analysis was conducted. Carlos PĂ©rez-Ruixo was an employee of Janssen Pharmaceutical Companies at the time this analysis was conducted.
: All studies were conducted in accordance with principles for human experimentation as defined in the 1964 Declaration of Helsinki and were approved by the human investigational review board of each study center and by the competent authority of each country.
: Informed consent was obtained from each subject before enrollment in the studies after being advised of the potential risks and benefits of the study, as well as the investigational nature of the study.
: All authors revised the article for important intellectual content and provided final approval of the published version.
: The datasets generated and/or analyzed during the current study belong to Janssen Research & Development and are not publicly available.
: Not applicable.
: Carlos Perez Ruixo performed the population pharmacokinetic analysis, executed the model-based simulations, and took the lead in writing the manuscript. Stefaan Rossenu, Peter Zannikos, Partha Nandy, Jaskaran Singh, Wayne Drevets, and Juan Jose Perez Ruixo substantially contributed to the design of the clinical studies that were included in the analyses, reviewed early versions of the manuscript, contributed to the scientific content (including data analysis and interpretation of the results), and provided approval of the final version that was submitted for publication.